非小细胞肺癌患者组织中lncRNA MAGI2-AS3的表达及与病理参数和预后的关系

摘要
图/表
参考文献(24)
相关文章 (15)

全文: PDF (608 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨非小细胞肺癌（NSCLC）患者组织中长链非编码RNA（lncRNA）膜相关鸟苷酸激酶包含WW和PDZ结构域2-反义RNA 3（MAGI2-AS3）的表达及与病理参数和预后的关系。方法选取2016年8月至2018年8月南通大学附属丹阳市人民医院收治的103例NSCLC患者，检测癌组织与癌旁组织中lncRNA MAGI2-AS3表达，分析lncRNA MAGI2-AS3表达与NSCLC患者病理参数的关系。根据lncRNA MAGI2-AS3表达水平将患者分为高lncRNA MAGI2-AS3表达组（≥lncRNA MAGI2-AS3表达均值）和低lncRNA MAGI2-AS3表达组（＜lncRNA MAGI2-AS3表达均值）。Kaplan-Meier法绘制NSCLC患者术后3年生存曲线，多因素Cox回归分析NSCLC患者预后影响因素。结果 NSCLC组织中lncRNA MAGI2-AS3表达低于癌旁组织，差异有统计学意义（P ＜ 0.05）。不同TNM分期、淋巴结转移患者lncRNA MAGI2-AS3表达比较，差异有统计学意义（P ＜ 0.05）。高lncRNA MAGI2-AS3表达组（51例）中位生存时间长于低lncRNA MAGI2-AS3表达组（52例），差异有统计学意义（P ＜ 0.05）。多因素Cox回归分析显示，肿瘤分化程度、TNM分期、淋巴结转移情况、lncRNA MAGI2-AS3表达水平是NSCLC患者预后不良的影响因素（P ＜ 0.05）。结论 NSCLC组织中lncRNA MAGI2-AS3低表达，与TNM分期、淋巴结转移、预后不良有关，可作为NSCLC患者预后评估指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杨广惠1 潘慧敏2 查丽芬2 顾俊1

关键词 ：非小细胞肺癌, 长链非编码RNA, 膜相关鸟苷酸激酶包含WW和PDZ结构域-2反义RNA 3, 预后

Abstract：Objective To investigate the expression of long non-coding RNA (lncRNA) membrane associated guanylate kinase, WW, and PDZ domain containing two-antisense RNA three (MAGI2-AS3) in non-small cell lung cancer (NSCLC) patient tissues and the relationship with pathological parameters and prognosis. Methods One hundred and three patients with NSCLC admitted to Danyang People’s Hospital Affiliated to Nantong University from August 2016 to August 2018 were selected. The expressions of lncRNA MAGI2-AS3 in cancer tissues and adjacent tissues were detected. The relationship between lncRNA MAGI2-AS3 expression and pathological parameters of NSCLC patients was analyzed. According to lncRNA MAGI2-AS3 expression level, patients were divided into high lncRNA MAGI2-AS3 expression group (≥ mean lncRNA MAGI2-AS3 expression level) and low lncRNA MAGI2-AS3 expression group (< mean lncRNA MAGI2-AS3 expression level). The three-year survival curve of NSCLC patients was drawn by using Kaplan-Meier method. Prognostic factors of NSCLC patients were analyzed by using multi-factor Cox regression. Results The expression of lncRNA MAGI2-AS3 in NSCLC tissues was lower than that in adjacent tissues, the difference was statistically significant (P < 0.05). There were significant differences in the expression of lncRNA MAGI2-AS3 in patients with different TNM stages and lymph node metastasis (P < 0.05). The median survival time of high lncRNA MAGI2-AS3 expression group (51 cases) was longer than that of low lncRNA MAGI2-AS3 expression group (52 cases), the difference was statistically significant (P < 0.05). Multivariate Cox regression analysis showed that degree of tumor differentiation, TNM stage, lymph node metastasis, and expression level of lncRNA MAGI2-AS3 were influencing factors for poor prognosis in patients with NSCLC (P < 0.05). Conclusion The low expression of lncRNA MAGI2-AS3 in NSCLC tissues is related to TNM stage, lymph node metastasis, and poor prognosis, which can be used as a prognostic indicator for NSCLC patients.

Key words： Non-small cell lung cancer Long non-coding RNA Membrane associated guanylate kinase, WW, and PDZ domain containing two-antisense RNA three Prognosis

基金资助:江苏省卫生健康委医学科研项目（JH19012）。

通讯作者: 顾俊（1976.10-），男，博士，主任医师；研究方向：肺恶性肿瘤、呼吸介入诊疗技术。

引用本文:

杨广惠1 潘慧敏2 查丽芬2 顾俊1. 非小细胞肺癌患者组织中lncRNA MAGI2-AS3的表达及与病理参数和预后的关系[J]. 中国医药导报, 2022, 19(20): 104-107.
YANG Guanghui1 PAN Huimin2 ZHA Lifen2 GU Jun1. Expression of lncRNA MAGI2-AS3 in tissues of patients with non-small cell lung cancer and the relationship with pathological parameters and prognosis. 中国医药导报, 2022, 19(20): 104-107.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I20/104

[1] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] 中华医学会病理学分会，国家病理质控中心，中华医学会肿瘤学分会肺癌学组，等.非小细胞肺癌分子病理检测临床实践指南（2021版）[J].中华病理学杂志，2021，50（4）：323-332.
[3] 周彩存，王洁，王宝成，等.中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）[J].中国肺癌杂志，2021，24（4）：217-235.
[4] Ali Syeda Z，Langden SSS，Munkhzul C，et al. Regulatory mechanism of microRNA expression in cancer [J]. Int J Mol Sci，2020，21（5）：1723.
[5] Xu X，Yuan X，Ni J，et al. MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2 [J]. J Cell Physiol，2021，236（2）：1116-1130.
[6] Shen D，Xu J，Cao X，et al. Long noncoding RNA MAGI2-AS3 inhibits bladder cancer progression through MAGI2/PTEN/epithelial-mesenchymal transition （EMT） axis [J]. Cancer Biomark，2021，30（2）：155-165.
[7] 王冰，苏崇玉，刘志东.lncRNA MAGI2-AS3在非小细胞肺癌组织中的表达及生物学作用[J].现代肿瘤医学，2021， 29（19）：3385-3389.
[8] Li F，Hu Q，Pang Z，et al. LncRNA MAGI2-AS3 upregulates cytokine signaling 1 by sponging miR-155 in non-small cell lung cancer [J]. Cancer Biother Radiopharm，2020，35（1）：72-76.
[9] Wauters E，Vansteenkiste J. Acquired resistance in NSCLC：the journey from clinical definition to molecular understanding [J]. Ann Oncol，2021，32（12）：1463-1465.
[10] Park HR，Kim TM，Lee Y，et al. Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFRT790M-mutant NSCLC [J]. J Thorac Oncol，2021，16（11）：1859-1871.
[11] Qiu B，Cai K，Chen C，et al. Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer [J]. Transl Lung Cancer Res，2021，10（9）：3713-3736.
[12] Andreano A，Bergamaschi W，Russo AG. Immune checkpoint inhibitors at any treatment line in advanced NSCLC：real-world overall survival in a large Italian cohort [J]. Lung Cancer，2021，159：145-152.
[13] 张競文，续倩，李国亮.癌症发生发展中的表观遗传学研究[J].遗传，2019，41（7）：567-581.
[14] Chao YL，Pecot CV. Targeting epigenetics in lung cancer [J]. Cold Spring Harb Perspect Med，2021，11（6）：a038000.
[15] Nair L，Chung H，Basu U. Regulation of long non-coding RNAs and genome dynamics by the RNA surveillance machinery [J]. Nat Rev Mol Cell Biol，2020，21（3）：123-136.
[16] Zhang W，Tang G，Zhou S，et al. LncRNA-miRNA interaction prediction through sequence-derived linear neighborhood propagation method with information combination [J]. BMC Genomics，2019，20（Suppl 11）：946.
[17] Zhou Y，Sun W，Qin Z，et al. LncRNA regulation：new frontiers in epigenetic solutions to drug chemoresistance [J]. Biochem Pharmacol，2021，189：114228.
[18] Ku GW，Kang Y，Yu SL，et al. LncRNA LINC00240 suppresses invasion and migration in non-small cell lung cancer by sponging miR-7-5p [J]. BMC Cancer，2021， 21（1）：44.
[19] Geng Q，Li Z，Li X，et al. LncRNA NORAD，sponging miR-363-3p，promotes invasion and EMT by upregulating PEAK1 and activating the ERK signaling pathway in NSCLC cells [J]. J Bioenerg Biomembr，2021，53（3）：321-332.
[20] Li D，Wang J，Zhang M，et al. LncRNA MAGI2-AS3 is regulated by BRD4 and promotes gastric cancer progression via maintaining ZEB1 overexpression by sponging miR-141/200a [J]. Mol Ther Nucleic Acids，2020，19：109-123.
[21] Liu F，Deng W，Wan Z，et al. lncRNA MAGI2-AS3 overexpression had antitumor effect on hepatic cancer via miRNA-23a-3p/PTEN axis [J]. Food Sci Nutr，2021，9（5）：2517-2530.
[22] Pérez-Ramírez C，Ca?觡adas-Garre M，Molina M?譧，et al. PTEN and PI3K/AKT in non-small-cell lung cancer [J]. Pharmacogenomics，2015，16（16）：1843-1862.
[23] 吴春娇，马丽霞，王艳萍，等.抑癌基因PTEN在非小细胞肺癌中表达及其与非小细胞肺癌的相关性[J].中国老年学杂志，2021，41（7）：1399-1401.
[24] Hao XZ，Yang K. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis [J]. Eur Rev Med Pharmacol Sci，2019，23（17）：7399-7407.